Prescient Therapeutics Limited (PTX.AX)

0.0410 0.0000 (0.00%) At close: 04:10PM AEST

Prescient Therapeutics Limited

100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://ptxtherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Steven Lee Yatomi-Clarke	MD, CEO & Director	638.85k	N/A	N/A
Ms. Melanie Jaye Leydin B.Bus, C.A.	CFO & Company Secretary	158.4k	N/A	1973
Upaly Bahadure	Director of Clinical Affairs & Operations	N/A	N/A	N/A
Dr. Terrence G. Chew	Chief Medical Officer	155.99k	N/A	1947
Ms. Rebecca Lim	Senior Vice President of Scientific Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Corporate governance

Prescient Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.